Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24058

Title: Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)
Authors: Oreja-Guevara, C.
Alroughani, R.
Brassat, D.
Boyko, A. N.
McCombe, P.
Steingo, B.
Van Wijmeersch, Bart
Margolin, D. H.
Thangavelu, K.
Rodriguez, C. E.
Vermersch, P.
Issue Date: 2016
Citation: MULTIPLE SCLEROSIS JOURNAL, 22, p. 648-649 (Art N° P1232)
Notes: [Oreja-Guevara, C.] Univ Hosp San Carlos, Madrid, Spain. [Alroughani, R.] Amiri Hosp, Sharq, Kuwait. [Brassat, D.] Univ Toulouse, Purpan Hosp, Toulouse, France. [Brassat, D.] Univ Toulouse, Mixed Unit Res 1043, Toulouse, France. [Boyko, A. N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, A. N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia. [Steingo, B.] Ft Lauderdale Multiple Sclerosis Ctr, Ft Lauderdale, FL USA. [Van Wijmeersch, B.] Univ Hasselt, Rehabil & MS Ctr Overpelt BIOMED, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.] Sanofi Genzyme, Cambridge, MA USA. [Vermersch, P.] Univ Lille, Lille, France.
URI: http://hdl.handle.net/1942/24058
Link to publication: https://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/145915/celia.oreja-guevara.durable.improvement.in.clinical.outcomes.in.html?f=p6m3e1031o14008
ISI #: 000383267202431
ISSN: 1352-4585
Category: M
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version248.8 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.